Development and synthesis of novel heterocyclic scaffolds tyrosine kinase inhibitors as anticancer agents

dc.contributor.guide	Khan, Tabassum
dc.coverage.spatial
dc.creator.researcher	Likhar, Rupali
dc.date.accessioned	2025-05-23T10:27:10Z
dc.date.available	2025-05-23T10:27:10Z
dc.date.awarded	2024
dc.date.completed	2023
dc.date.registered	2019
dc.description.abstract	File attached newline
dc.description.note	Location-Knowledge Resource Centre, Kalina
dc.format.accompanyingmaterial	CD
dc.format.dimensions	30*21
dc.format.extent	xxiv, 289p
dc.identifier.researcherid
dc.identifier.uri	http://hdl.handle.net/10603/641297
dc.language	English
dc.publisher.institution	Pharmaceutical Chemistry SVKMs Dr Bhanuben Nanavati College of Pharmacy
dc.publisher.place	Mumbai
dc.publisher.university	University of Mumbai
dc.relation
dc.rights	university
dc.source.university	University
dc.subject.keyword	Clinical Pre Clinical and Health
dc.subject.keyword	Pharmacology and Toxicology
dc.subject.keyword	Pharmaceutical chemistry
dc.subject.keyword	EGFR inhibitors
dc.subject.keyword	Breast cancer
dc.subject.keyword	Lung cancer
dc.subject.keyword	4(3H)-Quinazolinone-1,3,4-oxadiazole fused heterocyclic derivatives
dc.subject.keyword	Anticancer activity
dc.title	Development and synthesis of novel heterocyclic scaffolds tyrosine kinase inhibitors as anticancer agents
dc.title.alternative
dc.type.degree	Ph.D.